Sign In
Last checked at 
25 Jun 2025 07:00
25 June 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Development and licensing agreement with global life sciences leader
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce a new development and licensing agreement with an established global company in the life sciences and diagnostics sector, part of a major multinational conglomerate (the "Partner").
Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC) assays and diagnostic kits, leveraging its proprietary Optimer®-Fc platform, which produces aptamer binders with an antibody Fc-tag optimised for IHC workflows. The Partner will fully fund the development work, which is expected to be completed within a 12-month timeline, for an undisclosed sum. Subject to development and validation, the Optimer®-Fc reagent is anticipated to be incorporated into commercial IHC kits, with a product launch expected within the current calendar year.
The agreement includes a commercial licensing arrangement, under which Aptamer will receive royalties of 2% on net sales of all assay kits containing the licensed Optimer®-Fc reagent, subject to standard minimum royalty commitments. The kits are expected to be distributed through recognised global channels specialising in life sciences research products.
This partnership strengthens Aptamer's recurring revenue potential and supports its strategy to expand the application of its Optimer platform in high-value life sciences markets. The collaboration with a globally respected industry leader underscores the commercial potential and technical capabilities of Aptamer's Optimer®-Fc technology for advanced diagnostic applications.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:
"We are pleased to collaborate with a leading global life sciences company to develop this Optimer®-Fc reagent for IHC applications. The royalty structure and fully funded development provide a clear path to revenue generation and validate the strength of our Optimer platform. This agreement enhances our portfolio of royalty-generating assets and supports our mission to deliver innovative solutions to the life sciences industry."
Certain details of the agreement, including specific financial terms and the identity of the Partner, are commercially sensitive and have not been disclosed at this stage. The Company will provide updates on material developments as appropriate.
- Ends -
For further information, please contact:
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer | +44 (0) 1904 217 404 |
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat | +44 (0) 20 3368 3550 |
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
Northstar Communications Limited - Investor Relations Sarah Hollins | +44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
Follow the stocks
